What is Crohn’s and Inflammatory Bowel Disease?

Crohn’s disease causes small intestine inflammation and usually occurs in the lower small intestine.  That is not to say it cannot affect any part of the digestive tract, from the mouth on down. The inflammation can cause a tremendous amount of pain, diarrhea and other discomforts.

The general name for afflictions such as Crohn’s disease is IBD (inflammatory bowel disease).  The IBD group also includes irritable bowel syndrome and ulcerative colitis.  Statistics show that about 20 percent of people with Crohn’s have a relative with some form of IBD.

 

How can Emu Oil help Crohn’s / IBD?

We are by no means physicians here, and cannot give medical advice.  However, logic tells us since Emu Oil studies have shown that Emu Oil is a natural anti-inflammatory, and Crohn’s/IBD is an inflammatory disease, it may help reduce the inflammation naturally. Ingesting Emu Oil dietary supplements will take the Emu Oil directly into the digestive tract, right to the source of inflammation.

In a U of M study (2001) conducted for inflammation, it concludes that Emu Oil reduces the degree of inflammation between 42% and 71% in mice with auricular (ear) swelling due to Croton oil.  The Doctor conducting the studies reported the results to be “incredible”.

See below for the study:

Emu Oil Increases Colonic Crypt Depth in A Rat Model of Ulcerative Colitis.

 

By Abimosleh SMLindsay RJButler RNCummins AGHowarth GS.

BACKGROUND:

Current treatments for the inflammatory bowel diseases, encompassing Crohn’s disease and ulcerative colitis, are variably effective. Emu oil, extracted from emu fat, predominantly comprises fatty acids, with purported claims of anti-inflammatory properties.

AIM:

We evaluated Emu Oil for its potential to ameliorate dextran sulphate sodium (DSS)-induced colitis in rats.

METHODS:

Male Sprague-Dawley Rats were allocated to treatment groups (n = 8). Groups 1 and 2 consumed water and were gavaged (1 ml) daily with water (group 1) or Emu Oil (group 2) from days 0 to 10. Groups 3-6 ingested 2% DSS in the drinking water from days 5 to 10 and were gavaged from days 0 to 10 with water (group 3), 0.5 ml Emu Oil (group 4) or 1 ml Emu Oil (group 5). Group 6 received 1 ml Emu Oil after commencing DSS treatment (days 6-10). Disease activity index, metabolic parameters, (13)C-sucrose breath test, and histological colonic damage severity and crypt depth were assessed.

RESULTS:

Emu Oil in DSS-treated rats reduced colonic damage severity compared to DSS-controls (up to threefold; P < 0.001). In DSS-treated rats, crypts in the proximal colon were lengthened by 0.5 ml emu oil (373 ± 18 μm), compared with DSS-controls (302 ± 8 μm); whilst in the distal colon (DSS control: 271 ± 17 μm), crypt depth was greater following 0.5 ml emu oil (352 ± 22 μm) and 1 ml Emu Oil (341 ± 9 μm) and also when emu oil was administered post-DSS commencement (Group 6: 409 ± 16 μm; P < 0.05). Emu oil did not significantly affect other parameters of colonic architecture.

CONCLUSIONS:

Emu oil improved tissue damage associated with colitis, suggesting its potential as a unique formulation to augment conventional treatment approaches for IBD.